Recently, we reported a novel conversion therapy strategy of TACE combined with tyrosine kinase inhibitor (TKI) and PD-1 inhibitor for patients with unresectable HCC at the 2022 American Society of Clinical Oncology Gastrointestinal (ASCO-GI) Cancers Symposium (28). Here, PDCD1 is linked to hepatocellular carcinoma.